The C-Terminal Fragment of Prostate-Specific Antigen,a 2331 Da Peptide,as a New Urinary Pathognomonic Biomarker Candidate for Diagnosing Prostate Cancer |
| |
Authors: | Kenji Nakayama Takahiro Inoue Sadanori Sekiya Naoki Terada Yu Miyazaki Takayuki Goto Shigeki Kajihara Shin-Ichiro Kawabata Shinichi Iwamoto Kuniko Ikawa Junko Oosaga Hiroaki Tsuji Koichi Tanaka Osamu Ogawa |
| |
Institution: | 1. Department of Urology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.; 2. Koichi Tanaka Laboratory of Advanced Science and Technology, Shimadzu Corporation, Nakagyou-ku, Kyoto, Japan.; 3. Department of Clinical Laboratory, Kyoto University Hospital, Sakyo-ku, Kyoto, Japan.; Innsbruck Medical University, Austria, |
| |
Abstract: | Background and ObjectivesProstate cancer (PCa) is one of the most common cancers and leading cause of cancer-related deaths in men. Mass screening has been carried out since the 1990s using prostate-specific antigen (PSA) levels in the serum as a PCa biomarker. However, although PSA is an excellent organ-specific marker, it is not a cancer-specific marker. Therefore, the aim of this study was to discover new biomarkers for the diagnosis of PCa.Materials and MethodsWe focused on urine samples voided following prostate massage (digital rectal examination DRE]) and conducted a peptidomic analysis of these samples using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/MSn). Urinary biomaterials were concentrated and desalted using CM-Sepharose prior to the following analyses being performed by MALDI-TOF/MSn: 1) differential analyses of mass spectra; 2) determination of amino acid sequences; and 3) quantitative analyses using a stable isotope-labeled internal standard.ResultsMultivariate analysis of the MALDI-TOF/MS mass spectra of urinary extracts revealed a 2331 Da peptide in urine samples following DRE. This peptide was identified as a C-terminal PSA fragment composed of 19 amino acid residues. Moreover, quantitative analysis of the relationship between isotope-labeled synthetic and intact peptides using MALDI-TOF/MS revealed that this peptide may be a new pathognomonic biomarker candidate that can differentiate PCa patients from non-cancer subjects.ConclusionThe results of the present study indicate that the 2331 Da peptide fragment of PSA may become a new pathognomonic biomarker for the diagnosis of PCa. A further large-scale investigation is currently underway to assess the possibility of using this peptide in the early detection of PCa. |
| |
Keywords: | |
|
|